Abstract
Type II diabetes mellitus is a known cardiovascular risk factor and its prevalence continues to increase. A revolution in the Type II diabetes mellitus treatment has occurred with the arrival of new antidiabetic drugs, which are thought to compromise metformin place. We aim to review the pharmacology, available evidence and clinical aspects of metformin use in the era of new antidiabetics.
Papers of special note have been highlighted as: • of interest
References
- 1. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24), 2515 (2017).
- 2. IDF Diabetes Atlas (9th Edition). (2019). https://www.diabetesatlas.org/en/
- 3. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2020. Diabetes Care 43(Suppl. 1), S14–S31 (2020). • It includes concepts about diabetes that should be known.
- 4. . Abnormalities in insulin secretion in Type 2 diabetes mellitus. Diabetes Metab. 34, S43–S48 (2008).
- 5. Emerging Risk Factors Collaboration, Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet Lond. Engl. 375(9733), 2215–2222 (2010).
- 6. . Mortality and causes of death in Type 2 diabetic patients: a long-term follow-up study in Osaka District, Japan. Diabetes Res. Clin. Pract. 7(1), 33–40 (1989).
- 7. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N. Engl. J. Med. 373(22), 2117–2128 (2015).
- 8. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N. Engl. J. Med. 377(7), 644–657 (2017).
- 9. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med. 380(4), 347–357 (2019).
- 10. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in Type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166), 31–39 (2019).
- 11. Cardiovascular outcomes with ertugliflozin in Type 2 diabetes. N. Engl. J. Med. 383(15), 1425–1435 (2020).
- 12. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381(21), 1995–2008 (2019).
- 13. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N. Engl. J. Med. 375(4), 311–322 (2016).
- 14. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 375(19), 1834–1844 (2016).
- 15. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193), 121–130 (2019).
- 16. Albiglutide and cardiovascular outcomes in patients with Type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157), 1519–1529 (2018).
- 17. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in Type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation 139(17), 2022–2031 (2019).
- 18. Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 381(9), 841–851 (2019).
- 19. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study. BMJ. 369, m1186 (2020).
- 20. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43(6), 1326–1335 (2020).
- 21. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41(2), 255–323 (2020). • Its comes from the European Society of Cardiology and the European Association for the study of Diabetes Task force and it aims to guide management of diabetes and prediabetes specifically in patients with cardiovascular disease.
- 22. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 43(Suppl. 1), S98–S110 (2020). • Its reading cannot be ignored, as it reflects the evidence and therapeutic practice recommendations of American Diabetes Association. It is a well-done document to review pharmacologic treatment of Type 2 diabetes mellitus and it collects the new evidence that endorses of SGLT2i and GLP1-RA use. Practical recommendations of metformin use are also reflected.
- 23. . Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30(5), 359–371 (1996).
- 24. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50(2), 81–98 (2011).
- 25. . Understanding the glucoregulatory mechanisms of metformin in Type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15(10), 569–589 (2019). • We chose this work because of its comprehensive review of pathways involved in the action of metformin.
- 26. . New insights into the anti-diabetic actions of metformin: from the liver to the gut. Expert Rev. Gastroenterol. Hepatol. 11(2), 157–166 (2017).
- 27. . Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br. J. Clin. Pharmacol. 12(2), 235–246 (1981).
- 28. . Mechanism of increase in plasma intact GLP-1 by metformin in Type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res. Clin. Pract. 106(1), e3–e6 (2014).
- 29. . Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists. J. Am. Coll. Cardiol. 75(16), 1956–1974 (2020).
- 30. . Efficacy of metformin in Type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 103(6), 491–497 (1997).
- 31. . Efficacy of metformin on glycemic control and weight in drug-naive Type 2 diabetes mellitus patients: a systematic review and meta-analysis of placebo-controlled randomized trials. Thérapie
doi: 10.1016/j.therap.2018.01.006 (2018) (Epub ahead of print). - 32. . Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care 35(2), 446–454 (2012).
- 33. . Metformin monotherapy for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3), CD002966 (2005).
- 34. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed Type 2 diabetes. Diabetes 51(12), 3479–3485 (2002).
- 35. . Effects of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes Obes. 21(5), 323–329 (2014).
- 36. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41(1), 111–188 (2020).
- 37. Effects of metformin on metabolite profiles and LDL cholesterol in patients with Type 2 diabetes. Diabetes Care 38(10), 1858–1867 (2015).
- 38. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in Type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257(1), 100–109 (2005).
- 39. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2(2), 116–124 (2014).
- 40. . Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed Type 2 diabetes mellitus: a cohort study. PeerJ. 6, e4578 (2018).
- 41. . The effect of metformin on blood pressure, plasma cholesterol and triglycerides in Type 2 diabetes mellitus: a systematic review. J. Intern. Med. 256(1), 1–14 (2004).
- 42. US renal data system 2018 Annual Data Report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 73(3), A7–A8 (2019).
- 43. American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes−2020. Diabetes Care 43(Suppl. 1), S135–S151 (2020).
- 44. The long-term effects of metformin on patients with Type 2 diabetic kidney disease. Diabetes Care 43(5), 948–955 (2020).
- 45. . Metformin treatment in patients with Type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 41(3), 547–553 (2018).
- 46. . Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease. Curr. Opin. Nephrol. Hypertens. 26(5), 375–383 (2017).
- 47. . Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 121(2), 149–157.e2 (2008).
- 48. American Diabetes Association. 3. Prevention or delay of Type 2 diabetes: standards of medical care in diabetes—2020. Diabetes Care 43(Suppl. 1), S32–S36 (2020).
- 49. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol. Assess. Winch. Engl. 22(18), 1–64 (2018).
- 50. . Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc. Diabetol. 18(1), 54 (2019).
- 51. Cardiovascular and metabolic effects of metformin in patients with Type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5(8), 597–609 (2017).
- 52. . Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp. Clin. Endocrinol. Diabetes 121(1), 27–31 (2013).
- 53. . Effects of Metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. 338(26), 1876–1880 (1998).
- 54. . Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst. Rev. (3), CD003053 (2003).
- 55. . Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 60(9), 1639–1647 (2017).
- 56. . Anticancer activity of metformin: a systematic review of the literature. Future Sci. OA 5(8), FSO410 (2019).
- 57. . Metformin as an anticancer agent. Trends Pharmacol. Sci. 39(10), 867–878 (2018).
- 58. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 9(40), 25808–25825 (2018).
- 59. . Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27(12), 2184–2195 (2016).
- 60. . The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag. Res. 11, 3295–3313 (2019).
- 61. . Metformin and its benefits for various diseases. Front. Endocrinol. 11, 191 (2020).
- 62. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352(9131), 854–865 (1998). • It is a classical trial that supports metformin use and analyze cardiovascular outcomes.
- 63. . 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008).
- 64. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with Type 2 diabetes mellitus. Arch. Intern. Med. 169(6), 616–625 (2009).
- 65. Effects of metformin versus glipizide on cardiovascular outcomes in patients with Type 2 diabetes and coronary artery disease. Diabetes Care 36(5), 1304–1311 (2013).
- 66. Diabetes medications as monotherapy or metformin-based combination therapy for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164(11), 740–751 (2016).
- 67. . Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc. Diabetol. 18(1), 96 (2019).
- 68. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction. Circulation 140(12), 1004–1014 (2019).
- 69. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and Reduced kidney function. JAMA 1–11 (2019).
- 70. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc. Disord. 14, 129 (2014).
- 71. . Metformin use is associated with a lower risk of hospitalization for heart failure in patients with Type 2 diabetes mellitus: a retrospective cohort analysis. J. Am. Heart Assoc. 8(21), e011640 (2019). • A good retrospective cohort to review the potential role of metformin in reducing heart failure hospitalization.
- 72. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the survival and ventricular enlargement (SAVE) study fn1fn1 this study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada. J. Am. Coll. Cardiol. 29(2), 229–236 (1997).
- 73. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 39(33), 3021–3104 (2018).
- 74. Combination of insulin and metformin in the treatment of Type 2 diabetes. Diabetes Care 25(12), 2133–2140 (2002).
- 75. . Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet. Med. J. Br. Diabet. Assoc. 24(4), 350–358 (2007).
- 76. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed Type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet Lond. Engl. 394(10208), 1519–1529 (2019).
- 77. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naïve Type 2 diabetes. Diabetes Care 39(3), 353–362 (2016).
- 78. . Dapagliflozin, metformin XR, or both: initial pharmacotherapy for Type 2 diabetes, a randomised controlled trial. Int. J. Clin. Pract. 66(5), 446–456 (2012).
- 79. . Initial combination of empagliflozin and metformin in patients with Type 2 diabetes. Diabetes Care 39(10), 1718–1728 (2016).
- 80. The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Sci. Rep. 6(1), 32714 (2016).
- 81. . Glucose and hemoglobin A 1c. Lab. Med. 45(1), e21–e24 (2014).
- 82. 6. Glycemic targets: standards of medical care in diabetes—2020. 43, 11 (2020).
- 83. . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 Years: overview. Diabetes Care 37(1), 9–16 (2014).
- 84. Sodium-glucose cotransporter 2 inhibitors for Type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 159(4), 262–274 (2013).
- 85. . Glucagon-like peptide 1 receptor agonists for Type 2 diabetes. Diabetes Spectr. 30(3), 202–210 (2017).
- 86. . Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J. Am. Coll. Cardiol. 75(4), 422–434 (2020).
- 87. . GLP-1RAs in Type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc. Diabetol. 17(1), 157 (2018).
- 88. . Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus. Cochrane Database Syst. Rev. (1), CD002967 (2010).
- 89. . Cardiovascular outcomes of Type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res. Care. 8(1), e001451 (2020).
- 90. . Polypills for primary prevention of cardiovascular disease. Nat. Rev. Cardiol. 16(10), 602–611 (2019).